Prioritize Advanced Therapies in Crohn Disease

March 2026

You’ll see more advanced therapies in moderate to severe Crohn disease on home med lists...due to updated guidelines.

Previous guidelines suggested early use of biologics, with or withOUT immunomodulators (azathioprine, etc).

Now, guidelines are more streamlined, suggesting up front use of “advanced therapies”...including the newer interleukin (IL)-23 antagonists risankizumab (Skyrizi), guselkumab (Tremfya), and mirikizumab (Omvoh).

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote